Abstracts Archive - Page 2072 of 2607 - ACR Meeting Abstracts

Abstract Number: 2449 • 2014 ACR/ARHP Annual Meeting
Microrna-346 Regulation of Follicular Helper T Cells Is Involved in the Pathogenesis of rheumatoid Arthritis Disease
Xinyi Tang¹, Jie Ma² and Shengjun Wang³, ¹Department of Laboratory Medicine, Jiangsu University Affi�liated People’s Hospital, Zhenjiang, China, ²Department of Laboratory Medicine, Jiangsu University Afﬁliated People’s Hospital, Zhenjiang, China, ³Department of Laboratory Medicine, Jiangsu University Affiliated People’s Hospital, Zhenjiang, China
Background/Purpose Follicular helper T (Tfh) cells have been identified as a new subset of effector helper T cells that are essential in regulating the development…
Abstract Number: 2450 • 2014 ACR/ARHP Annual Meeting
Downregulation of Mirna-196a and Its Downstream HOXC8 Target Gene in Rheumatoid Arthritis Synovial Fibroblasts
Maria Filkova¹, Michelle Trenkmann¹, Borbala Aradi-Vegh¹, Lenka Pleštilová¹, Joanna Stanczyk¹, Beat A. Michel², Ladislav Senolt³, Renate Gay¹, Steffen Gay⁴ and Astrid Juengel¹, ¹Center of Experimental Rheumatology, University Hospital Zurich, Zurich Schlieren, Switzerland, ²Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁴Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose Comprehensive analysis of 260 miRNAs suggested a downregulation of miR-196a in rheumatoid arthritis (RA) synovial fibroblasts (SF) compared with osteoarthritis (OA) SF. Mature miR-196a…
Abstract Number: 2451 • 2014 ACR/ARHP Annual Meeting
Mir-155 Expression Correlates with Clinical Disease Activity and Has Effector Function in Rheumatoid Arthritis
Aziza Elmesmari¹, Derek G. Gilchrist², Mariola Kurowska-Stolarska³ and Iain B. McInnes⁴, ¹Immunology, Institute of Infection,Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: MicroRNAs are fine tuners of biological pathways that function via post-transcriptional regulation of target mRNA life span. MicroRNA 155 (miR155) is particularly implicated in…
Abstract Number: 2452 • 2014 ACR/ARHP Annual Meeting
Protective Effect of the IL33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
Raquel López-Mejías¹, Fernanda Genre¹, Mercedes García-Bermúdez², Alfonso Corrales¹, Carlos González-Juanatey³, Begoña Ubilla¹, J. Llorca⁴, Encarnación Amigo⁵, Jose A. Miranda-Filloy⁶, Trinitario Pina Murcia¹, Ricardo Blanco⁷, Santos Castañeda⁸, Javier Martin⁹ and Miguel A González-Gay¹, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Immunology and Cellular Biology, Instituto de Parasitologia y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ³Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁵Hospital Universitario Lucus Augusti, Rheumatology Division, Lugo, Spain, ⁶Rheumatology, Division of Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ⁷Hospital Marques de Valdecilla, Santander, Spain, ⁸Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ⁹Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain
Background/Purpose: Rheumatoid arthritis (RA) is a complex inflammatory disease characterized by chronic inflammation, accelerated atherosclerosis and increased cardiovascular (CV) mortality. Interleukin 33 (IL-33) is a…
Abstract Number: 2413 • 2014 ACR/ARHP Annual Meeting
Similar Response Rates to Anti-Tumor Necrosis Factor and Non- Anti-Tumor Necrosis Factor Biologic Therapies in Ethnic Minority Patients at 6 Months
Gail S. Kerr¹, Yusuf Yazici², Christopher Swearingen³, Luis R. Espinoza⁴, Edward L. Treadwell⁵, Yvonne Sherrer⁶, Angelia Mosley-WIlliams⁷, Ignacio Garcia-Valladares⁸, Rodolfo Perez Alamino⁹, Sharon Dowell¹⁰, Mercedes Quinones¹¹, Akgun Ince¹², Theresa Lawrence Ford¹³, Chunqiao Luo¹⁴, Adrian Godoy¹⁰ and John Amatruda¹⁵, ¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Pediatrics and Biostatistics, University of Arkansas, Little Rock, AR, ⁴Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA, ⁵Dept Medicine Div of Rheum, East Carolina University, Greenville, NC, ⁶Rheum/Immunology, Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, ⁷Rheumatology, Detroit VAMC, Detroit, MI, ⁸Immunology and Rheumatology, Hospital General de Occidente, Zapopan, Jal., Mexico, ⁹internal Medicine, LSUHSC, New Orleans, LA, ¹⁰Division of Rheumatology, Howard University, Washington, DC, ¹¹Division of Rheumatology, Howard University Hospital, Washington, DC, ¹²Arthitis Consultants Inc, St. Louis University, St. Louis, MO, ¹³North Georgia Rheumatology Group, PC, Lawrenceville, GA, ¹⁴University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁵Rheumatology, Howard University, Washington, DC
Similar Response Rates to Anti-Tumor Necrosis Factor and Non- Anti-Tumor Necrosis Factor Biologic Therapies in Ethnic Minority Patients Background/Purpose: Biologic therapies have expanded the treatment…
Abstract Number: 2414 • 2014 ACR/ARHP Annual Meeting
Etanercept in Mono Therapy or in Combination with MTX: Results from a Sub Analysis of a German Non-Interventional Study
Karl Heinz Goettl¹, Markus Gaubitz², Andreas Krause³, Udo Lendl⁴, Ralph Lippe⁴, Thomas Meng⁴ and Peter-Andreas Loeschmann⁵, ¹Joint practice for internal medicine, Passau, Germany, ²Academy of manual diagnostic at University of Münster, Münster, Germany, ³Konigstr. 63, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁴Pfizer Pharma GmbH, Berlin, Germany, ⁵Loeschmann, Berlin, Germany
Background/Purpose Although a combination with MTX is recommended for all biologics, data from different registries around the world show that in real life around 30%…
Abstract Number: 2415 • 2014 ACR/ARHP Annual Meeting
Characteristics of Rheumatoid Arthritis Patients Not Receiving Early Initiation of Disease Modifying Therapy
Dimitrios A. Pappas^1,2, Jeffery D. Kent³, Jeffrey D. Greenberg^2,4, Marc Mason², Joel M. Kremer⁵, Amy Y. Grahn³ and Robert J. Holt⁶, ¹Columbia University, New York, NY, ²Corrona, LLC., Southborough, MA, ³Horizon Pharma, Inc., Deerfield, IL, ⁴Rheumatology, New York University School of Medicine, New York, NY, ⁵Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁶University of Illinois - Chicago, Chicago, IL
Background/Purpose : Early and aggressive therapy of Rheumatoid Arthritis (RA) with Disease Modifying Anti-Rheumatic Agents (DMARDs), glucocorticoids, and biologic agents is recommended by current treatment…
Abstract Number: 2416 • 2014 ACR/ARHP Annual Meeting
Do Patterns of Joint Swelling or Tenderness in Rheumatoid Arthritis Patients Impact Disease Activity Outcomes and Pain? Implications for Clinical Practice
Regan Arendse¹, John Kelsall², J. Antonio Avina-Zubieta³, Philip Baer⁴, Erica Weinberg⁴, Jude Rodrigues⁵, Algis Jovaisas⁶, Isabelle Fortin⁷, Maqbool Sheriff⁸, Majed M. Khraishi⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Susan Otawa¹² and Allen J Lehman¹², ¹University of Saskatchewan, Saskatoon, SK, Canada, ²The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Private Practice, Scarborough, ON, Canada, ⁵Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁶194 Main Street, University of Ottawa, Ottawa, ON, Canada, ⁷Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁸Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁹Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose This analysis aimed to describe the pattern of specific joint involvement (tender and/or swollen) pre- and post-TNFi treatment and the impact of specific joint…
Abstract Number: 2417 • 2014 ACR/ARHP Annual Meeting
Is Remission Really Achievable in EARLY Rheumatoid Arthritis?
Olga Addimanda¹, Pierluigi Macchioni², Andrea Caruso¹, Niccolò Possemato¹, Mariagrazia Catanoso¹ and Carlo Salvarani², ¹S.C. Reumatologia, Arcispedale Santa Maria Nuova, I.R.C.C.S., Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy
Background/Purpose: : to stress the need of routine use of US imaging in treat to target strategies aiming to achieve remission in early rheumatoid arthritis.…
Abstract Number: 2418 • 2014 ACR/ARHP Annual Meeting
Treatment Pattern and Direct Cost of Biologics for Rheumatoid Arthritis Patients: A Real-World Analysis of Nationwide Japanese Claims Data
Naonobu Sugiyama M.D., Ph.D¹, Tatsunori Murata, M.S.², Yosuke Morishima³, Yuri Fukuma⁴, Yoshiyuki Shibasaki⁴ and Lisa Marshall⁵, ¹Medical Affairs, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ²Health Economics Research Group, CRECON Research and Consulting Inc., Tokyo, Japan, ³RA & Inflammation Area Medical Affairs Department, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ⁴Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ⁵Inflammation Immunology Disease Group, Pfizer Inc. Inflammation Immunology Disease Group, Collegeville, PA
Background/Purpose Biologics such as etanercept (ETN), adalimumab (ADA), infliximab (IFX) and tocilizumab (TCZ) have led dramatic improvement in the treatment of rheumatoid arthritis (RA), but…
Abstract Number: 2419 • 2014 ACR/ARHP Annual Meeting
Efficacy of Biologic Medications in Active Rheumatoid Arthritis: A Systematic Review
Lynden Roberts^1,2, Kathleen Tymms³, Julien de Jager⁴, Geoffrey Littlejohn⁵, Hedley Griffiths⁶, David Nicholls⁷, Paul Bird⁸, Jennifer Young⁹ and Jane Zochling¹⁰, ¹JCU Clinical School, Townsville, QLD, Australia, ²Monash Medical Centre, Clayton, VIC, Australia, ³Canberra Rheumatology, Canberra, ACT, Australia, ⁴Olser House, Southport, QLD, Australia, ⁵Rheumatology, Monash Medical Centre and Monash University, Clayton, VIC, Australia, ⁶Barwon Rheumatology Service, Geelong, VIC, Australia, ⁷Coast Joint Care, Maroochydore, QLD, Australia, ⁸Combined Rheumatology Practice, Sydney, NSW, Australia, ⁹4-10 Inman Road, Roche Products Pty Limited, Sydney, NSW, Australia, ¹⁰Department of Rheumatology, Menzies Research Institute Tasmania, Hobart, TAS, Australia
Background/Purpose: In the last decade, biologic medications have transformed the management of RA. The effectiveness of these medications has been reported in numerous randomized controlled…
Abstract Number: 2420 • 2014 ACR/ARHP Annual Meeting
Quality Assessment of Controlled Trials Evaluating Chinese Herbal Medicine in Patients with Rheumatoid Arthritis: a Systematic Review
Xin Pan^1,2, Maria A. Lopez-Olivo², Pratibha Nayak³ and Maria E. Suarez-Almazor⁴, ¹Department of Rheumatology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, ²Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Chinese herbal medicine (CHM) is a mainstay in the treatment of rheumatoid arthritis (RA) in China. We conducted a systematic review to appraise the…
Abstract Number: 2421 • 2014 ACR/ARHP Annual Meeting
Patient Treatment Goals in Rheumatoid Arthritis: Results of Focus Groups Among Rheumatologists, English and Spanish-Speaking Patients
Jennifer Barton¹, Christopher J. Koenig², Diana Martinez³, Gina Evans-Young⁴, Patricia P. Katz¹ and Edward H. Yelin⁵, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, UCSF, San Francisco, CA, ³UCSF/San Francisco General Hospital, San Francisco, CA, ⁴Rheumatology, UCSF, San Francisco, CA, ⁵Arthritis Research Group, University of California, San Francisco, San Francisco, CA
Background/Purpose: Treatment guidelines in rheumatoid arthritis (RA) frame provider's therapeutic goal as disease remission. Although goal concordance between providers and patients has been shown to…
Abstract Number: 2422 • 2014 ACR/ARHP Annual Meeting
A Tailored Approach to Reduce Dose of TNF Inhibitors Is Equally Effective, but Substantially Less Costly Than Standard Dosing in Patients with Rheumatoid Arthritis over One and Two Years: A Prospective Cohort Study
Jakub Zavada¹, Michal Uher², Katarina Sisol³, Sarka Forejtova⁴, Katerina Jarosova⁵, Liliana Sedova³, Zuzana Urbanova⁶, Olga Sleglova⁶, Jiri Vencovsky⁷ and Karel Pavelka⁸, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ³rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁴Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁵Na Slupi 4, Institute of Rheumatology, Prague, Czech Republic, ⁶Institute of Rheumatology, Prague, Czech Republic, ⁷Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁸Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: To compare effectiveness and costs of standard versus individually tailored reduced doses of TNF inhibitors (TNFi) in patients with Rheumatoid Arthritis (RA) after achieving…
Abstract Number: 2423 • 2014 ACR/ARHP Annual Meeting
Prevalence of Subclinical Synovitis Detected By Ultrasound in Rheumatoid Arthritis and Psoriatic Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
José M. Senabre-Gallego¹, José Rosas-Gómez de Salazar¹, Esteban Salas-Heredia¹, Gregorio Santos-Soler¹, Francisca Llinares-Tello², Carlos Santos-Ramirez³, Mabel Sánchez-Barrioluengo⁴, Xavier Barber-Vallés⁵, Rafaela Ortega³, Ana Pons¹, Catalina Cano¹ and Maria Luisa Lorente-Betoret¹, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ³Rheumatology, Hospital Marina Salud, Denia, Spain, ⁴Ingenio (CSIC-UPV), Universitat Politècnica de València, Valencia, Spain, ⁵Center of Operations Research, University Miguel Hernández, Elche, Spain
Background/Purpose To estimate the prevalence of subclinical synovitis detected by ultrasound in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients in clinical remission receiving anti-TNFα…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].